Actively Recruiting
Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
Led by Hospices Civils de Lyon · Updated on 2025-06-11
100
Participants Needed
4
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study consists of having participants complete quality of life questionnaires (PROMs) at the time of the cures +/- one week and in the middle of the intercure time +/- one week. As all the collection times do not correspond to a consultation or a visit to a medical service, The investigator wanted to develop a remote, computerized data collection solution. Researchers have programmed an AURA-RIV-TNE care pathway (MOCAs: Engine for the organization and coordination of health acts) on the myHCL patient environment, taking up the course of the study presented in the form of a table in paragraph 6.2. Once the patient consents to participate in the study, he must create an account on the patient interface of his investigation center (myHCL, myCHUGA etc) as much as possible to facilitate data extraction. Once the patient consents to participate in the study, the MOCAs AURA-RIV-TNE course will be associated with him in the Easily software, by defining the date week 0 (baseline) of the first treatment. This will allow automated sending of MAIL and SMS reminders at each questionnaire time. The MAILs will contain an internet link allowing the participant to be directly written to the questionnaires to be completed. A reminder system will be possible if the patient does not complete the questionnaire.
CONDITIONS
Official Title
Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age >18 years;
- Patient starting treatment with RIV validated in the RENATEN RCP;
- Patient having received written information about the study;
- Collection of the patient's non-objection
- Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial;
- Patients undergoing re-treatment with RIV can be included;
You will not qualify if you...
- Persons deprived of their liberty by a judicial or administrative decision;
- Adults subject to a legal protection measure (guardianship, curatorship);
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
CHU de Saint-Etienne, Hôpital Nord
Saint-Priest-en-Jarez, Saint-Etienne, France, 42270
Actively Recruiting
2
CH Métropole Savoie
Chambéry, France, 73000
Actively Recruiting
3
Centre de Lutte Contre le Cancer Jean Perrin
Clermont-Ferrand, France, 63011
Actively Recruiting
4
Hospices Civils de Lyon, Hopital Lyon Sud
Lyon, France, 69495
Actively Recruiting
Research Team
N
Nicolas JACQUET-FRANCILLON, MD
CONTACT
A
Adeline MANSUY
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here